Acta Academiae Medicinae Sinica

Acta Academiae Medicinae Sinica

Acta Academiae Medicinae Sinica ›› 2011, Vol. 33 ›› Issue (6): 644-648.doi: 10.3881/j.issn.1000-503X.2011.06.012

• Original Articles • Previous Articles     Next Articles

Selection of Culture Media for the Mass Production of γδT Cells Used in Adoptive Immunotherapy

ZHOU Jian-hua, KANG Ning, CUI Lian-xian, HE Wei   

  1. Department of Immunology, Institute of Basic Medical Sciences, CAMS and PUMC, Beijing 100005, China
  • Received:2011-10-08 Revised:2012-01-04 Online:2011-12-20 Published:2011-12-20
  • Contact: HE Wei E-mail:heweiimu@public.bta.net.cn
  • Supported by:

    Supported by the National High Technology Research and Development Program of China(863 Program) (2006AA02Z480) and the National Natural Sciences Foundation of China(30972776)

Abstract: Objective To select the optimal culture media for the mass production of γδT cells used in adoptive immunotherapy. Methods Three different culture media (RPMI-1640, AIM-V, and OpTmizer, with or without autologous serum) were used to culture γδT cells. The survival rate, purity, proliferation efficiency, and biological functions of the expanded γδT cells were examined and compared. Results The survival rate of γδT cells expanded in RPMI-1640 decreased over culture time. The purities of γδT cells cultured in AIM-V or OpTmizer with or without serum were higher than those cultured in RPMI-1640. After two weeks of culture in the absence of serum, the purity and proliferation efficiency of γδT cells cultured in OpTmizer were significantly higher than those cultured in RPMI-1640 (P0.05). However, cells expanded in RPMI-1640 exhibited significantly weaker cytotoxicity against Daudi lymphoma cells than those expanded in OpTmizer (P<0.05) and AIM-V (P<0.05). Conclusion Due to low serum-dependence, high proliferation efficiency, and favorable biology function of expanded cells, OpTmizer is the most suitable medium for the mass production of γδT cells used in adoptive immunotherapy.

Key words: γδT cells, adoptive immunotherapy, culture medium

CLC Number: